Alector

Yahoo Finance • 17 days ago

Alector appoints Neil Berkley as chief financial officer

* Alector (ALEC [https://seekingalpha.com/symbol/ALEC]) said on Friday that Neil Berkley has been appointed CFO, effective December 10, 2025. * Berkley has served as Alector’s Chief Business Officer (CBO) since March 2024, and CBO and... Full story

Yahoo Finance • 28 days ago

Alector to Participate in the Bank of America CNS Therapeutics Conference

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today ann... Full story

Yahoo Finance • last month

ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“Alector” or “the Company”) (NASDAQ: AL... Full story

Yahoo Finance • 2 months ago

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson’s disease; both advancing t... Full story

Yahoo Finance • 2 months ago

Alector slumps on late-stage trial setback for GSK-partnered dementia candidate

[Brain puzzle missing a piece] PM Images Alector (NASDAQ:ALEC [https://seekingalpha.com/symbol/ALEC]) shares extended post-market losses to drop ~50% in the premarket on Wednesday after the neurology-focused biotech announced a Phase 3 tr... Full story

Yahoo Finance • 2 months ago

GSK : Latozinemab Fails To Meet Clinical Endpoint In INFRONT-3 FTD-GRN Trial

(RTTNews) - GSK plc. (GSK, GSK.L) and Alector, Inc. announced results from the INFRONT-3 clinical trial evaluating latozinemab in individuals with frontotemporal dementia caused by a mutation in the progranulin gene (FTD-GRN). While treat... Full story

Yahoo Finance • 2 months ago

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today ann... Full story

Yahoo Finance • 4 months ago

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, toda... Full story

Yahoo Finance • 5 months ago

Top stock movements in today's session.

Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT MRM... Full story

Yahoo Finance • 5 months ago

These stocks are moving in today's session

Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SGBX [https://w... Full story

Yahoo Finance • 5 months ago

Earnings call transcript: Alector beats Q2 2025 EPS and revenue forecasts

Alector Inc. (ALEC) reported its second-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of -$0.30 compared to the forecasted -$0.47, representing a surprise of 36.17%. The company also reported revenue of $7... Full story

Yahoo Finance • 6 months ago

3 Penny Stocks With Market Caps Over $80M To Watch Closely

The U.S. stock market has been navigating a wave of uncertainty, with recent tariff threats from President Trump causing fluctuations across major indices such as the Dow Jones, S&P 500, and Nasdaq. Amid these broader market dynamics, penn... Full story

Yahoo Finance • 7 months ago

Alector Provides Executive Leadership Update

--Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinic... Full story

Yahoo Finance • last year

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Alector, Inc. --Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)-- --Lato... Full story

Yahoo Finance • last year

Alector Second Quarter 2024 Earnings: Beats Expectations

Alector (NASDAQ:ALEC) Second Quarter 2024 Results Key Financial Results Revenue: US$15.1m (down 73% from 2Q 2023). Net loss: US$38.7m (down from US$1.38m profit in 2Q 2023). US$0.40 loss per share (down from US$0.016 profit in 2Q 2023).... Full story

Yahoo Finance • 2 years ago

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

Alector, Inc. The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE... Full story

Yahoo Finance • 2 years ago

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time. Continue reading... Full story

Yahoo Finance • 2 years ago

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the C... Full story

Yahoo Finance • 2 years ago

Alector to Participate in the Stifel Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel... Full story

Yahoo Finance • 2 years ago

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants Enrollment completed in the INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer’... Full story